## Hank F Kung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6612061/publications.pdf

Version: 2024-02-01

275 papers 15,355 citations

65 h-index 23472 111 g-index

279 all docs

279 docs citations

times ranked

279

11707 citing authors

#	Article	IF	CITATIONS
1	Use of Florbetapir-PET for Imaging $\hat{I}^2$ -Amyloid Pathology. JAMA - Journal of the American Medical Association, 2011, 305, 275.	3.8	927
2	In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand <sup>18</sup> F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine, 2010, 51, 913-920.	2.8	607
3	Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neuroscience Letters, 2000, 285, 107-110.	1.0	464
4	Preclinical Properties of <sup>18</sup> F-AV-45: A PET Agent for AÎ <sup>2</sup> Plaques in the Brain. Journal of Nuclear Medicine, 2009, 50, 1887-1894.	2.8	396
5	5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants. Neuron, 2010, 65, 40-52.	3.8	373
6	Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biological Psychiatry, 2003, 54, 960-971.	0.7	338
7	In-Vivo Imaging of Alzheimer Disease Â-Amyloid With [11C]SB-13 PET. American Journal of Geriatric Psychiatry, 2004, 12, 584-595.	0.6	283
8	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine, 2015, 7, 274ra17.	5.8	257
9	Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates., 1997, 25, 1-14.		246
10	Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery1. Academic Radiology, 2004, 11, 996-1004.	1.3	238
11	Structureâ <sup>^</sup> Activity Relationship of Imidazo[1,2-a]pyridines as Ligands for Detecting Î <sup>2</sup> -Amyloid Plaques in the Brain. Journal of Medicinal Chemistry, 2003, 46, 237-243.	2.9	217
12	F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting $\hat{Al^2}$ aggregates in the brain. Nuclear Medicine and Biology, 2005, 32, 799-809.	0.3	217
13	11C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimer's disease. Nuclear Medicine and Biology, 2003, 30, 565-571.	0.3	212
14	IMPY: an improved thioflavin-T derivative for in vivo labeling of $\hat{l}^2$ -amyloid plaques. Brain Research, 2002, 956, 202-210.	1.1	204
15	Imaging of dopamine transporters in humans with technetium-99m TRODAT 1. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1527-1530.	2.2	201
16	Congo red and thioflavinâ€T analogs detect Aβ oligomers. Journal of Neurochemistry, 2008, 104, 457-468.	2.1	198
17	Novel Stilbenes as Probes for Amyloid Plaques. Journal of the American Chemical Society, 2001, 123, 12740-12741.	6.6	181
18	<sup>18</sup> F Stilbenes and Styrylpyridines for PET Imaging of Aβ Plaques in Alzheimer's Disease: A Miniperspective. Journal of Medicinal Chemistry, 2010, 53, 933-941.	2.9	179

#	Article	IF	Citations
19	Serotonin-1A Autoreceptors Are Necessary and Sufficient for the Normal Formation of Circuits Underlying Innate Anxiety. Journal of Neuroscience, 2011, 31, 6008-6018.	1.7	169
20	2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nuclear Medicine and Biology, 2000, 27, 249-254.	0.3	151
21	PET Imaging of Glutaminolysis in Tumors by <sup>18</sup> F-( <i>2S,4R</i> )4-Fluoroglutamine. Journal of Nuclear Medicine, 2011, 52, 1947-1955.	2.8	149
22	Synthesis and Characterization of Technetium-99m-Labeled Tropanes as Dopamine Transporter-Imaging Agents. Journal of Medicinal Chemistry, 1997, 40, 9-17.	2.9	147
23	Isoindol-1-one Analogues of 4-(2â€~-methoxyphenyl)-1-[2â€~-[N-(2â€~â€~-pyridyl)-p-iodobenzamido]ethyl]piperazii (p-MPPI) as 5-HT1AReceptor Ligands. Journal of Medicinal Chemistry, 1998, 41, 157-166.	ne 2.9	145
24	F-18 Stilbenes as PET Imaging Agents for Detecting $\hat{I}^2$ -Amyloid Plaques in the Brain. Journal of Medicinal Chemistry, 2005, 48, 5980-5988.	2.9	145
25	Synthesis of Optically Pure 4-Fluoro-Glutamines as Potential Metabolic Imaging Agents for Tumors. Journal of the American Chemical Society, 2011, 133, 1122-1133.	6.6	144
26	Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [1231]IPT and single-photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 415-421.	2.2	136
27	PET/SPECT imaging agents for neurodegenerative diseases. Chemical Society Reviews, 2014, 43, 6683-6691.	18.7	131
28	Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer's disease. Nuclear Medicine and Biology, 2002, 29, 633-642.	0.3	129
29	Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Research, 2004, 1025, 98-105.	1.1	129
30	[99mTc]TRODAT-1: A novel technetium-99m complex as a dopamine transporter imaging agent. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 372-380.	2.2	128
31	In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with <sup>18</sup> F-AV-133. Journal of Nuclear Medicine, 2010, 51, 223-228.	2.8	122
32	Preparation and Characterization of l-[5- $<$ sup>11 $<$ /sup>C]-Glutamine for Metabolic Imaging of Tumors. Journal of Nuclear Medicine, 2012, 53, 98-105.	2.8	117
33	Subcellular Localization of Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal Microscopy. Cancer Research, 2007, 67, 6708-6716.	0.4	112
34	Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With ${\rm A}\hat{\rm I}^2$ Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue. Alzheimer Disease and Associated Disorders, 2012, 26, 8-16.	0.6	112
35	IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nuclear Medicine and Biology, 2001, 28, 887-894.	0.3	111
36	Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [ <sup>11</sup> C]McN 5652, [ <sup>11</sup> C]ADAM, [ <sup>11</sup> C]DASB, [ <sup>11</sup> C]DAPA, and [ <sup>11</sup> C]AFM. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1377-1398.	2.4	111

#	Article	IF	CITATIONS
37	Synthesis And Evaluation of 4-(2'-Methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI): A New Iodinated 5-HT1A Ligand. Journal of Medicinal Chemistry, 1994, 37, 1406-1407.	2.9	105
38	Mass effect of injected dose in small rodent imaging by SPECT and PET. Nuclear Medicine and Biology, 2005, 32, 673-678.	0.3	105
39	18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nuclear Medicine and Biology, 2007, 34, 89-97.	0.3	103
40	First Example of a 99mTc Complex as a Dopamine Transporter Imaging Agent. Journal of the American Chemical Society, 1995, 117, 11037-11038.	6.6	101
41	Novel Benzofuran Derivatives for PET Imaging of $\hat{I}^2$ -Amyloid Plaques in Alzheimer's Disease Brains. Journal of Medicinal Chemistry, 2006, 49, 2725-2730.	2.9	100
42	Small animal imaging with high resolution single photon emission tomography. Nuclear Medicine and Biology, 2003, 30, 889-895.	0.3	99
43	The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing. ACS Medicinal Chemistry Letters, 2012, 3, 265-267.	1.3	99
44	Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. Journal of Nuclear Medicine, 2006, 47, 748-54.	2.8	99
45	p-[18F]-MPPF: A potential radioligand for PET studies of 5-HT1A receptors in humans. , 1997, 25, 147-154.		95
46	New brain perfusion imaging agents based on technetium-99m bis(aminoethanethiol) complexes: stereoisomers and biodistribution. Journal of Medicinal Chemistry, 1989, 32, 433-437.	2.9	93
47	In Vivo Imaging of $\hat{I}^2$ -Cell Mass in Rats Using <sup>18</sup> F-FP-(+)-DTBZ: A Potential PET Ligand for Studying Diabetes Mellitus. Journal of Nuclear Medicine, 2008, 49, 1171-1176.	2.8	90
48	A rapid one-step radiosynthesis of theβ-amyloid imaging radiotracerN-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole([11C]-6-OH-BTA-1). Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 679-682.	0.5	88
49	Synthesis and Evaluation of <sup>18</sup> F-Labeled 2-Phenylbenzothiazoles as Positron Emission Tomography Imaging Agents for Amyloid Plaques in Alzheimer's Disease. Journal of Medicinal Chemistry, 2009, 52, 1428-1437.	2.9	87
50	Enantioselective Radiosynthesis of Positron Emission Tomography (PET) Tracers Containing [ <sup>18</sup> F]Fluorohydrins. Journal of the American Chemical Society, 2014, 136, 5291-5294.	6.6	85
51	Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide. Journal of Medicinal Chemistry, 1988, 31, 1039-1043.	2.9	83
52	Synthesis and Characterization of Radioiodinated N-(3-lodopropen-1-yl)-2.betacarbomethoxy-3.beta(4-chlorophenyl)tropanes: Potential Dopamine Reuptake Site Imaging Agents. Journal of Medicinal Chemistry, 1994, 37, 1535-1542.	2.9	82
53	Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain. Synapse, 2000, 38, 403-412.	0.6	81
54	The Fluorescent Congo Red Derivative, (Trans,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 72 Td (Trans)â^1-Bromo-2,	,5-Bis-(3-Hy 1.9	ydroxycarbony 81
34	Sheet Structures in Postmortem Human Neurodegenerative Disease Brains. American Journal of Pathology, 2001, 159, 937-943.	1.9	61

4

#	Article	IF	Citations
55	Comparative Evaluation of <sup>18</sup> F-Labeled Glutamic Acid and Glutamine as Tumor Metabolic Imaging Agents. Journal of Nuclear Medicine, 2012, 53, 1616-1624.	2.8	81
56	Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 2002, 5, 111-3.	1.0	80
57	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of <sup>18</sup> F-(2 <i>S</i> ,4 <i>R</i> )-4-Fluoroglutamine. Radiology, 2018, 287, 667-675.	3.6	80
58	HIPDM Single Photon Emission Computed Tomography Brain Imaging in Partial Onset Secondarily Generalized Tonicâ€Clonic Seizures. Epilepsia, 1987, 28, 305-311.	2.6	79
59	Synthesis and characterization of iodobenzamide analogs: potential D-2 dopamine receptor imaging agents. Journal of Medicinal Chemistry, 1990, 33, 171-178.	2.9	78
60	Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nuclear Medicine and Biology, 2006, 33, 685-694.	0.3	76
61	[18F](2 <i>S</i> ,4 <i>R</i> )4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. Cancer Research, 2017, 77, 1476-1484.	0.4	75
62	Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nuclear Medicine and Biology, 2001, 28, 657-666.	0.3	71
63	Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nuclear Medicine and Biology, 2007, 34, 239-246.	0.3	71
64	Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors. Neuropsychopharmacology, 1995, 12, 335-345.	2.8	70
65	IPT: A novel iodinated ligand for the CNS dopamine transporter. Synapse, 1995, 20, 316-324.	0.6	68
66	In vivo detection of stem cells grafted in infarcted rat myocardium. Journal of Nuclear Medicine, 2005, 46, 816-22.	2.8	67
67	A New Single-Photon Emission Computed Tomography Imaging Agent for Serotonin Transporters:  [123I]IDAM, 5-lodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl Alcohol. Journal of Medicinal Chemistry, 1999, 42, 333-335.	2.9	66
68	Pharmacological effects of dopaminergic drugs on in vivo binding of [ 99m Tc]TRODAT-1 to the central dopamine transporters in rats. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 25, 31-39.	3.3	65
69	Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Seminars in Nuclear Medicine, 2003, 33, 2-13.	2.5	63
70	Metabolic Imaging of Glutamine in Cancer. Journal of Nuclear Medicine, 2017, 58, 533-537.	2.8	63
71	Florbetapir F-18: A Histopathologically Validated Beta-Amyloid Positron Emission Tomography Imaging Agent. Seminars in Nuclear Medicine, 2011, 41, 300-304.	2.5	62
72	Tc-99m-Labeled Tropanes as Dopamine Transporter Imaging Agents. Bioconjugate Chemistry, 1996, 7, 421-429.	1.8	61

#	Article	IF	Citations
73	Specificity of Diastereomers of [99mTc]TRODAT-1 as Dopamine Transporter Imaging Agents. Journal of Medicinal Chemistry, 1998, 41, 428-436.	2.9	61
74	Fluoro-pegylated (FPEG) Imaging Agents Targeting Al $^2$ Aggregates. Bioconjugate Chemistry, 2007, 18, 238-246.	1.8	61
75	Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1377-1398.	2.4	60
76	A potential 5-HT1A receptor antagonist: p-MPPI. Life Sciences, 1994, 55, 1459-1462.	2.0	59
77	Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography. Applied Radiation and Isotopes, 2009, 67, 88-94.	0.7	58
78	Characterization of [ 123 I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 844-853.	3.3	57
79	Quick Assembly of 1,4-Diphenyltriazoles as Probes Targeting $\hat{I}^2$ -Amyloid Aggregates in Alzheimer's Disease. Journal of Medicinal Chemistry, 2007, 50, 3380-3387.	2.9	55
80	Embryonic Stem Cell Grafting in Normal and Infarcted Myocardium: Serial Assessment with MR Imaging and PET Dual Detection. Radiology, 2009, 250, 821-829.	3.6	55
81	[ <sup>18</sup> F](2 <i>S</i> ,4 <i>S</i> )-4-(3-Fluoropropyl)glutamine as a Tumor Imaging Agent. Molecular Pharmaceutics, 2014, 11, 3852-3866.	2.3	55
82	In vivo binding of [1231]4-(2?-methoxy phenyl)-1-[2?-(N-2?-pyridinyl)-P-iodobenzamido-]ethyl-piperazine, p-MPPI, to 5-HT1A receptors in rat brain. Synapse, 1994, 18, 359-366.	0.6	54
83	Biphenyls labeled with technetium 99m for imaging $\hat{l}^2$ -amyloid plaques in the brain. Nuclear Medicine and Biology, 2005, 32, 171-184.	0.3	53
84	Short Communication New 5-HT1A receptor antagonist: [3H]p-MPPF., 1996, 23, 344-346.		49
85	A Stereoselective Synthesis ofdl-threo-Methylphenidate: Preparation and Biological Evaluation of Novel Analoguesâ€. Journal of Organic Chemistry, 1998, 63, 9628-9629.	1.7	49
86	Simplified reference region model for the kinetic analysis of [99m Tc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 518-526.	3.3	49
87	Isomerization of (Z,Z) to (E,E)1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in Strong Base:Â Probes for Amyloid Plaques in the Brain. Journal of Medicinal Chemistry, 2001, 44, 2270-2275.	2.9	49
88	Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. Nuclear Medicine and Biology, 2001, 28, 505-508.	0.3	48
89	Dimethylamino-fluorenes: ligands for detecting $\hat{l}^2$ -amyloid plaques in the brain. Nuclear Medicine and Biology, 2003, 30, 573-580.	0.3	48
90	New PET Imaging Agent for the Serotonin Transporter:Â [18F]ACF (2-[(2-Amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). Journal of Medicinal Chemistry, 2002, 45, 4716-4723.	2.9	47

#	Article	IF	CITATIONS
91	Small and Neutral TcvO BAT, Bisaminoethanethiol (N2S2) Complexes for Developing New Brain Imaging Agents. Nuclear Medicine and Biology, 1998, 25, 135-140.	0.3	45
92	Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nuclear Medicine and Biology, 2006, 33, 203-209.	0.3	45
93	Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nuclear Medicine and Biology, 2007, 34, 233-237.	0.3	45
94	Novel Styrylpyridines as Probes for SPECT Imaging of Amyloid Plaques. Journal of Medicinal Chemistry, 2007, 50, 2157-2165.	2.9	45
95	Radioiodine-labeled N,N-dimethyl-N'-[2-hydroxy-3-alkyl-5-iodobenzyl]-1,3-propanediamines for brain perfusion imaging. Journal of Medicinal Chemistry, 1983, 26, 121-125.	2.9	44
96	Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT. Nuclear Medicine and Biology, 2007, 34, 787-789.	0.3	44
97	In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([1251]-IBZM): A potential imaging ligand for D-2 dopamine receptors in spect. Life Sciences, 1988, 42, 2097-2104.	2.0	43
98	Multidentate $\langle \sup 18 \rangle 18 \langle \sup F$ -Polypegylated Styrylpyridines As Imaging Agents for A $\hat{I}^2$ Plaques in Cerebral Amyloid Angiopathy (CAA). Journal of Medicinal Chemistry, 2011, 54, 8085-8098.	2.9	42
99	N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters. Journal of Nuclear Medicine, 2003, 44, 1890-7.	2.8	42
100	Detection of Amyloid Plaques by Radioligands for $\hat{A}^240$ and $\hat{A}^242$ : Potential Imaging Agents in Alzheimer's Patients. Journal of Molecular Neuroscience, 2003, 20, 15-24.	1.1	41
101	Design, synthesis, and structure–activity relationship of novel thiophene derivatives for β-amyloid plaque imaging. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1350-1352.	1.0	41
102	lodinated tomoxetine derivatives as selective ligands for serotonin and norepinephrine uptake sites. Journal of Medicinal Chemistry, 1992, 35, 4492-4497.	2.9	39
103	Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. Nuclear Medicine and Biology, 2010, 37, 917-925.	0.3	39
104	Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. Journal of Nuclear Medicine, 2004, 45, 834-41.	2.8	39
105	In vivo imaging of vesicular monoamine transporter 2 in pancreas using an 18F epoxide derivative of tetrabenazine. Nuclear Medicine and Biology, 2008, 35, 825-837.	0.3	38
106	An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2. Nuclear Medicine and Biology, 2010, 37, 133-141.	0.3	38
107	In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. Nuclear Medicine and Biology, 2010, 37, 479-486.	0.3	38
108	In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease. Archives of Neurology, 2011, 68, 905.	4.9	38

#	Article	IF	CITATIONS
109	Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin (trans) Tj ETQq1 1 0.7843	314 rgBT	/Overlock 10 T
110	The 5-HT1A Receptor Antagonist p-MPPI Blocks Responses Mediated by Postsynaptic and Presynaptic 5-HT1A Receptors. Pharmacology Biochemistry and Behavior, 1997, 57, 301-307.	1.3	37
111	Differential Diagnosis in AlzheimerÂ's Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. Neurodegenerative Diseases, 2012, 10, 161-165.	0.8	37
112	Derivatives of 4-(2'-Methoxyphenyl)-1-[2'-(N-2''-pyridinyl-p-iodobenzamido)ethyl]piperazine (p-MPPI) as 5-HT1A Ligands. Journal of Medicinal Chemistry, 1994, 37, 4572-4575.	2.9	36
113	Peracetic acid as a superior oxidant for preparation of [123I]IBZM: A potential dopamine D-2 receptor imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 1989, 27, 691-700.	0.5	35
114	Selective binding of 2-[1251]iodo-nisoxetine to norepinephrine transporters in the brain. Nuclear Medicine and Biology, 2004, 31, 533-541.	0.3	35
115	Automatic segmentation of dynamic neuroreceptor single-photon emission tomography images using fuzzy clustering. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 581-590.	3.3	34
116	Facile Synthesis [5-13C-4-2H2]-L-Glutamine for Hyperpolarized MRS Imaging of Cancer Cell Metabolism. Academic Radiology, 2011, 18, 932-939.	1.3	34
117	Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging. Nuclear Medicine and Biology, 2011, 38, 501-508.	0.3	34
118	Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20719-20724.	3.3	34
119	New conformationally restricted technetium-99m N2S2 complexes as myocardial perfusion imaging agents. Journal of Medicinal Chemistry, 1992, 35, 157-162.	2.9	33
120	New technetium 99m-labeled brain perfusion imaging agents. Seminars in Nuclear Medicine, 1990, 20, 150-158.	2.5	32
121	Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate. Journal of Neurology, 2002, 249, 1116-1118.	1.8	32
122	In Vivo Quantitative Noninvasive Imaging of Gene Transfer by Single-Photon Emission Computerized Tomography. Human Gene Therapy, 2003, 14, 255-261.	1.4	32
123	Synthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agents. Nuclear Medicine and Biology, 2012, 39, 933-943.	0.3	32
124	Synthesis and evaluation of a novel urea-based 68 Ga-complex for imaging PSMA binding in tumor. Nuclear Medicine and Biology, 2018, 59, 36-47.	0.3	32
125	lodinated 2-Aminotetralins and 3-Amino-1-benzopyrans: Ligands for Dopamine D2 and D3 Receptors. Journal of Medicinal Chemistry, 1994, 37, 4245-4250.	2.9	31
126	Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1714-1718.	3.3	31

#	Article	IF	Citations
127	Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer's disease. Journal of Molecular Neuroscience, 2002, 19, 7-10.	1.1	31
128	New Diphenylacetylenes as Probes for Positron Emission Tomographic Imaging of Amyloid Plaques. Journal of Medicinal Chemistry, 2007, 50, 2415-2423.	2.9	31
129	Synthesis of fluorescent probes based on stilbenes and diphenylacetylenes targeting $\hat{l}^2$ -amyloid plaques. Tetrahedron Letters, 2008, 49, 3395-3399.	0.7	31
130	(.+)-7-Chloro-8-hydroxy-1-(4'-[125I]iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine: a potential CNS D-1 dopamine receptor imaging agent. Journal of Medicinal Chemistry, 1989, 32, 1431-1435.	2.9	30
131	Single-photon emission tomography imaging of serotonin transporters in the non-human primate brain with the selective radioligand [ 123 l]IDAM. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 854-861.	3.3	30
132	Synthesis and Screening of a Library of Re/Tc-Based Amyloid Probes Derived from $\hat{l}^2$ -Breaker Peptides. Bioconjugate Chemistry, 2008, 19, 1087-1094.	1.8	30
133	Current and future radiopharmaceuticals for brain imaging with single photon emission computed tomography. Seminars in Nuclear Medicine, 1990, 20, 290-302.	2.5	29
134	Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Research, 1997, 747, 219-229.	1.1	29
135	2-(2-(Dimethylaminomethyl)phenoxy)-5-iodophenylamine:Â An Improved Serotonin Transporter Imaging Agent. Journal of Medicinal Chemistry, 2004, 47, 5258-5264.	2.9	29
136	<sup>68</sup> Ga-Bivalent Polypegylated Styrylpyridine Conjugates for Imaging AÎ <sup>2</sup> Plaques in Cerebral Amyloid Angiopathy. Bioconjugate Chemistry, 2016, 27, 1314-1323.	1.8	29
137	Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography., 1996, 24, 322-333.		28
138	Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5026-5028.	1.0	28
139	Radiosynthesis and biological evaluation of a promising Ïf2-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Applied Radiation and Isotopes, 2010, 68, 2268-2273.	0.7	28
140	Binding of 1251-iodoviny ltetrabenazine to CNS vesicular monoamine transport sites. Synapse, 1994, 18, 225-232.	0.6	27
141	Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease. Nuclear Medicine and Biology, 2005, 32, 329-335.	0.3	27
142	Synthesis and resolution of (.+)-7-chloro-8-hydroxy-1-(3'-iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor. Journal of Medicinal Chemistry, 1991, 34, 877-883.	2.9	26
143			

#	Article	IF	Citations
145	2-(2′-((Dimethylamino)methyl)-4′-(fluoroalkoxy)-phenylthio)benzenamine Derivatives as Serotonin Transporter Imaging Agents. Journal of Medicinal Chemistry, 2007, 50, 6673-6684.	2.9	26
146	In vivo SPECT imaging of 5-HT1A receptors with [123I]p-MPPI in nonhuman primates., 1996, 24, 273-281.		25
147	Creatine Kinase, a Magnetic Resonance-Detectable Marker Gene for Quantification of Liver-Directed Gene Transfer. Human Gene Therapy, 2005, 16, 1429-1438.	1.4	25
148	$2-(2\hat{a}\in^2-((Dimethylamino)methyl)-4\hat{a}\in^2-(3-[18F]fluoropropoxy)-phenylthio)$ benzenamine for positron emission tomography imaging of serotonin transporters. Nuclear Medicine and Biology, 2008, 35, 447-458.	0.3	25
149	SPECT Imaging of Herpes Simplex Virus Type 1 Thymidine Kinase Gene Expression By [1231]FIAU1. Academic Radiology, 2005, 12, 798-805.	1.3	24
150	A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent. Nuclear Medicine and Biology, 2008, 35, 83-90.	0.3	24
151	Dicarboxylate diamide dimercaptide (N2S2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals. Journal of Medicinal Chemistry, 1993, 36, 1032-1040.	2.9	23
152	Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1413-1423.	3.3	23
153	In Vivo Characterization of a Series of <sup>18</sup> F-Diaryl Sulfides ( <sup>18</sup> F-2-(2′-((Dimethylamino)Methyl)-4′-(Fluoroalkoxy)Phenylthio)Benzenamine) for PET Imaging of the Serotonin Transporter. Journal of Nuclear Medicine, 2009, 50, 1509-1517.	2.8	23
154	Synthesis of selenium-75 labeled tertiary diamines: new brain imaging agents. Journal of Medicinal Chemistry, 1980, 23, 1127-1130.	2.9	22
155	Characterization of Radioiodinated TISCH: A High-Affinity and Selective Ligand for Mapping CNS D1Dopamine Receptor. Journal of Neurochemistry, 1992, 58, 227-236.	2.1	22
156	Neutral and stereospecific Tc-99m complexes: [99mTc]N-benzyl-3,4-di-(N-2-mercaptoethyl)-aminopyrrolidines (P-BAT). Nuclear Medicine and Biology, 1999, 26, 217-224.	0.3	22
157	Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine. Clinical Nuclear Medicine, 2018, 43, e392-e399.	0.7	22
158	Synthesis and characterization of neutral oxotechnetium(V) bisaminoethanethiol complexes: potential brain imaging agents. Polyhedron, 1992, 11, 1145-1155.	1.0	21
159	Synthesis of (.+)-2'-trans-7-hydroxy-2-[N-(3'-iodo-2'-propenyl)-N-n-propylamino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand. Journal of Medicinal Chemistry, 1993, 36, 1499-1500.	2.9	21
160	Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor. Nuclear Medicine and Biology, 1994, 21, 179-188.	0.3	21
161	Expanding the Scope of Fluorine Tags for PET Imaging. Science, 2013, 342, 429-430.	6.0	21
162	Synthesis and biodistribution of 99mTc-labeled piperidinyl bis(aminoethanethiol) complexes: potential brain perfusion imaging agents for single photon emission computed tomography. Journal of Medicinal Chemistry, 1988, 31, 1043-1047.	2.9	20

#	Article	IF	CITATIONS
163	New bisaminoethanethiol (BAT) ligands which form two interconvertible Tc-99m complexes. Nuclear Medicine and Biology, 1995, 22, 749-757.	0.3	20
164	In vivo imaging of serotonin transporters with [ 99m Tc]TRODAT-1 in nonhuman primates. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 342-347.	3.3	20
165	Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with [ 123 l]ODAM. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1359-1362.	3.3	20
166	New 68Ga-PhenA bisphosphonates as potential bone imaging agents. Nuclear Medicine and Biology, 2016, 43, 360-371.	0.3	20
167	A New [ <sup>68</sup> Ga]Ga-HBED-CC-Bisphosphonate as a Bone Imaging Agent. Molecular Pharmaceutics, 2020, 17, 1674-1684.	2.3	20
168	Synthesis and optical resolution of (R)- and (S)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand. Journal of Medicinal Chemistry, 1993, 36, 4308-4312.	2.9	19
169	Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging. Journal of Molecular Neuroscience, 2004, 24, 049-054.	1.1	19
170	Synthesis, uptake mechanism characterization and biological evaluation of 18F labeled fluoroalkyl phenylalanine analogs as potential PET imaging agents. Nuclear Medicine and Biology, 2011, 38, 53-62.	0.3	19
171	[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence. Molecular Imaging and Biology, 2020, 22, 752-763.	1.3	19
172	Synthesis and evaluation of 18F labeled FET prodrugs for tumor imaging. Nuclear Medicine and Biology, 2014, 41, 58-67.	0.3	18
173	PET Imaging of <sup>18</sup> F-(2 <i>5</i> ,4 <i>R</i> )4-Fluoroglutamine Accumulation in Breast Cancer: From Xenografts to Patients. Molecular Pharmaceutics, 2018, 15, 3448-3455.	2.3	18
174	4-lodotomoxetine: A novel ligand for serotonin uptake sites. Life Sciences, 1992, 51, 95-106.	2.0	17
175	Technetium-99m N,N'-Bis(2-mercapto-2-methylpropyl)-2-aminobenzylamine: Technetium-99m Complexes of a Novel Bis(aminoethanethiol) Ligand. Journal of Medicinal Chemistry, 1994, 37, 3282-3288.	2.9	17
176	Quantitative autoradiographic studies of dopamine D3 receptors in rat cerebellum using [125I]S(â^²)5-OH-PIPAT. Brain Research, 1997, 778, 89-98.	1.1	16
177	Synthesis and Evaluation of Three <sup>18</sup> F-Labeled Aminophenylbenzothiazoles as Amyloid Imaging Agents. Journal of Medicinal Chemistry, 2009, 52, 7090-7102.	2.9	16
178	FlipADAM: a potential new SPECT imaging agent for the serotonin transporter. Nuclear Medicine and Biology, 2010, 37, 577-586.	0.3	16
179	New F-18 Prosthetic Group via Oxime Coupling. Bioconjugate Chemistry, 2011, 22, 642-653.	1.8	16
180	Synthesis and comparative biological evaluation of l- and d-isomers of 18F-labeled fluoroalkyl phenylalanine derivatives as tumor imaging agents. Nuclear Medicine and Biology, 2011, 38, 301-312.	0.3	16

#	Article	IF	Citations
181	Decreased Striatal Vesicular Monoamine Transporter Type 2 Correlates With the Nonmotor Symptoms in Parkinson Disease. Clinical Nuclear Medicine, 2019, 44, 707-713.	0.7	16
182	Simulating technetium-99m cerebral perfusion studies with a three-dimensional Hoffman brain phantom: Collimator and filter selection in SPECT neuroimaging. Annals of Nuclear Medicine, 1996, 10, 153-160.	1.2	15
183	Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for $\hat{l}^2$ -amyloid plaques. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4823-4827.	1.0	15
184	Synthesis of 5-Fluoroalkylated Pyrimidine Nucleosides via Negishi Cross-Coupling. Journal of Organic Chemistry, 2008, 73, 4874-4881.	1.7	15
185	Dosimetry of iodine-123 iodobenzamide in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 747-752.	2.2	14
186	5-Chloro-2-(2′-((dimethylamino)methyl)-4′-iodophenylthio)benzenamine: a new serotonin transporter ligand. Nuclear Medicine and Biology, 2007, 34, 129-139.	0.3	14
187	Radioiodinated aza-diphenylacetylenes as potential SPECT imaging agents for $\hat{l}^2$ -amyloid plaque detection. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3581-3584.	1.0	14
188	18F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons. PET Clinics, 2010, 5, 75-82.	1.5	14
189	Overview of Radiopharmaceuticals for Diagnosis of Central Nervous Disorders. Critical Reviews in Clinical Laboratory Sciences, 1991, 28, 269-286.	2.7	13
190	Synthesis and preliminary evaluation of an iodovinyl-tetrabenazine analog as a marker for the vesicular monoamine transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 1993, 33, 355-368.	0.5	13
191	Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for $\hat{l}^2$ -amyloid plaques. Nuclear Medicine and Biology, 2009, 36, 411-417.	0.3	13
192	Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies. Nuclear Medicine and Biology, 2020, 86-87, 1-8.	0.3	13
193	Characterization of Radioiodinated Ligand Binding to Amyloid $\hat{l}^2$ Plaques. Journal of Molecular Neuroscience, 2003, 20, 249-254.	1.1	12
194	Application of n.c.a. 4-[18F]fluorophenol in diaryl ether syntheses of 2-(4-[18F]fluorophenoxy)-benzylamines. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 443-455.	0.5	12
195	IMPY, a potential $\hat{I}^2$ -amyloid imaging probe for detection of prion deposits in scrapie-infected mice. Nuclear Medicine and Biology, 2008, 35, 197-201.	0.3	12
196	Dynamic PET/CT imaging of 18F-(2S, 4R)4-fluoroglutamine in healthy volunteers and oncological patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2280-2292.	3.3	12
197	Amino- and amido-tetrabenazine derivatives: Synthesis and evaluation as potential ligands for the vesicular monoamine transporter. Nuclear Medicine and Biology, 1995, 22, 527-535.	0.3	11
198	Synthesis of radioiodinated 1-deoxy-nojirimycin derivatives: novel glucose analogs. Nuclear Medicine and Biology, 1999, 26, 833-839.	0.3	11

#	Article	IF	CITATIONS
199	Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3435-3438.	1.0	11
200	Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2012, 163, 108-120.	0.7	11
201	Imaging of VMAT2 binding sites in the brain by 18F-AV-133: The effect of a pseudo-carrier. Nuclear Medicine and Biology, 2012, 39, 897-904.	0.3	11
202	Synthesis, resolution and radioiodination of S(â^')trans-5-hydroxy-2-[N-n-propyl-N-(3′-iodo-2′-propenyl)amino]tetralin-S(â^')trans-5-OH-PIPAT: A new dopamine D2-like receptor ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 1051-1062.	0.5	10
203	Development of 99mTc-labelled complexes for imaging dopamine transporters in the brain. Transition Metal Chemistry, 1998, 23, 531-536.	0.7	10
204	One-step preparation of [18F]FPBM for PET imaging of serotonin transporter (SERT) in the brain. Nuclear Medicine and Biology, 2016, 43, 470-477.	0.3	10
205	Deuterated 18 F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent. Nuclear Medicine and Biology, 2018, 57, 42-49.	0.3	10
206	Synthesis and Evaluation of <sup>68</sup> Ga- and <sup>177</sup> Lu-Labeled ( <i>R</i> )- vs ( <i>S</i> )-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives. Molecular Pharmaceutics, 2020, 17, 4589-4602.	2.3	10
207	A New Highly Deuterated [ $<$ sup $>$ 18 $<$ /sup $>$ F]AV-45, [ $<$ sup $>$ 18 $<$ /sup $>$ F]D15FSP, for Imaging $\hat{I}^2$ -Amyloid Plaques in the Brain. ACS Medicinal Chemistry Letters, 2021, 12, 1086-1092.	1.3	10
208	Head-to-head comparison of [68ÂGa]Ga-P16-093 and [68ÂGa]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1052-1062.	3.3	10
209	Concentration recovery for SPECT CNS dopamine-receptor studies for monkeys. Medical Physics, 1994, 21, 675-681.	1.6	9
210	[125I](S)-trans-7-OH-PIPAT: A potential spect imaging agent for sigma binding sites. Life Sciences, 1994, 54, 593-603.	2.0	9
211	(R)-N-Methyl-3-(3-125I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters. Nuclear Medicine and Biology, 2008, 35, 43-52.	0.3	9
212	Synthesis of novel PEG-modified nitroimidazole derivatives via "hot-click―reaction and their biological evaluation as potential PET imaging agent for tumors. Journal of Radioanalytical and Nuclear Chemistry, 2017, 312, 263-276.	0.7	9
213	In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia. Molecular Pharmaceutics, 2019, 16, 1156-1166.	2.3	9
214	Synthesis and preliminary evaluation of a novel glutamine derivative: (2S,4S)4-[18F]FEBGln. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1047-1050.	1.0	9
215	(2S,4R)-4-[18F]Fluoroglutamine as a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application. Molecular Imaging and Biology, 2019, 21, 945-953.	1.3	9
216	Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Molecular Imaging and Biology, 2022, 24, 710-720.	1.3	9

#	Article	lF	CITATIONS
217	Synthesis and tissue distribution study of iodine-labeled benzyl- and xylylamines. Journal of Medicinal Chemistry, 1982, 25, 870-873.	2.9	8
218	[125I](±)FISCH: A new CNS D-1 dopamine receptor imaging ligand. Life Sciences, 1989, 45, 711-718.	2.0	8
219	Acute toxicity and mutagenicity of the copper complex of pyruvaldehyde-bis (N-4-methylthiosemicarbazone), Cu-PTSM. Journal of Applied Toxicology, 1990, 10, 417-421.	1.4	8
220	Synthesis and resolution of (.+)-7-chloro-8-hydroxy-1-(3'-iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor [Erratum to document cited in CA114(13):122017d]. Journal of Medicinal Chemistry, 1991, 34, 3405-3405.	2.9	8
221	Preparation of a technetium-99m SPECT agent for imaging the sigma-2 receptor status of solid tumors. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 899-908.	0.5	8
222	Synthesis and in Vitro Evaluation of 5-[18F]Fluoroalkyl Pyrimidine Nucleosides for Molecular Imaging of Herpes Simplex Virus Type 1 Thymidine Kinase Reporter Gene Expression. Journal of Medicinal Chemistry, 2008, 51, 5690-5701.	2.9	8
223	Study the effect of a pseudo-carrier on pharmacokinetics of 9-fluoropropyl-(+)-dihydrotetrabenazine in rat plasma by ultra-performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 505-510.	1.2	8
224	Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4303-4306.	1.0	8
225	Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([18F]AV-133). Neuroscience Bulletin, 2014, 30, 409-416.	1.5	8
226	Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [18F]AV-133 in mouse brain. Nuclear Medicine and Biology, 2015, 42, 630-636.	0.3	8
227	4-(((4-lodophenyl)methyl)-4 <i>H</i> -1,2,4-triazol-4-ylamino)-benzonitrile: A Potential Imaging Agent for Aromatase. Journal of Medicinal Chemistry, 2016, 59, 9370-9380.	2.9	8
228	VMAT2 imaging agent, D6-[18F]FP-(+)-DTBZ: Improved radiosynthesis, purification by solid-phase extraction and characterization. Nuclear Medicine and Biology, 2019, 72-73, 26-35.	0.3	8
229	[68Ga]Ga-HBED-CC-DiAsp: A new renal function imaging agent. Nuclear Medicine and Biology, 2020, 82-83, 17-24.	0.3	8
230	Development and validation of a kit formulation of [68Ga]Ga-P15-041 as a bone imaging agent. Applied Radiation and Isotopes, 2021, 169, 109485.	0.7	8
231	Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [ <sup>18</sup> F]AlF-P16-093. Bioconjugate Chemistry, 2021, 32, 1017-1026.	1.8	8
232	Preparation and biodistribution of 1-[2-(3-[1251]iodo-4-aminophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]piperazine and 1-[2-(3-[1251]iodo-4-azidophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]piperazine. Journal of Medicinal Chemistry, 1989, 32, 543-547.	2.9	7
233	Iodophenyl tagged sphingosine derivatives: Synthesis and preliminary biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3382-3385.	1.0	7
234	Synthesis and in vitro evaluation of 18F labeled tyrosine derivatives as potential positron emission tomography (PET) imaging agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3482-3485.	1.0	7

#	Article	IF	CITATIONS
235	Determination of the penetration of 9-fluoropropyl-(+)-dihydrotetrabenazine across the blood–brain barrier in rats by microdialysis combined with liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 3041-3046.	1.2	7
236	Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2962-2965.	1.0	7
237	Alanine and glycine conjugates of (2S,4R)-4-[18F]fluoroglutamine for tumor imaging. Nuclear Medicine and Biology, 2018, 60, 19-28.	0.3	7
238	Training the next generation of radiopharmaceutical scientists. Nuclear Medicine and Biology, 2020, 88-89, 10-13.	0.3	7
239	Preclinical evaluation of [18F]D3FSP, deuterated AV-45, for imaging of $\hat{l}^2$ -amyloid in the brain. Nuclear Medicine and Biology, 2021, 92, 97-106.	0.3	7
240	99mTc-Labeled MIBG Derivatives:Â Novel99mTc Complexes as Myocardial Imaging Agents for Sympathetic Neurons. Bioconjugate Chemistry, 1999, 10, 159-168.	1.8	6
241	Fluoride-18 radiolabeling of peptides bearing an aminooxy functional group to a prosthetic ligand via an oxime bond. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6992-6995.	1.0	6
242	An improved preparation of [18F]FPBM: A potential serotonin transporter (SERT) imaging agent. Nuclear Medicine and Biology, 2013, 40, 974-979.	0.3	6
243	I-123 Hydroxyiodobenzyl Propanediamine (HIPDM) Cerebral Blood Flow Imaging Demonstrating Transtentorial Diaschisis. Clinical Nuclear Medicine, 1990, 15, 623-629.	0.7	5
244	Synthesis of (+)-(R)- and (?)-(S)-trans-8-hydroxy-2-[N-n-propyl-N-(3?-iodo-2?-propenyl)] aminotetralin: New 5-HT1A receptor ligands. Chirality, 1995, 7, 452-458.	1.3	5
245	Deuteriumâ€substituted 2â€(2′â€((dimethylamino)methyl)â€4′â€{ <sup>18</sup> F](fluoropropoxy)phenylthio)benzenamine as a s transporter imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 576-585.	er <b>oto</b> nin	5
246	An improved preparation of [ <sup>18</sup> F]AVâ€45 by simplified solidâ€phase extraction purification. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 108-118.	0.5	5
247	Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer. Bioorganic and Medicinal Chemistry, 2020, 28, 115319.	1.4	5
248	$68$ Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic $\hat{l}^2$ -cell and insulinoma. Nuclear Medicine and Biology, 2021, 102-103, 87-96.	0.3	5
249	Mass spectral analysis diaminodithiol ligands used for the complexation of technetium-99m. Organic Mass Spectrometry, 1991, 26, 528-530.	1.3	4
250	Ultra-high resolution single photon emission tomography imaging of the mouse striatum. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 446-446.	3.3	4
251	5-[18F]Fluoroalkyl pyrimidine nucleosides: probes for positron emission tomography imaging of herpes simplex virus type 1 thymidine kinase gene expression. Nuclear Medicine and Biology, 2009, 36, 29-38.	0.3	4
252	Fluorination at the 4 position alters the substrate behavior of l-glutamine and l-glutamate: Implications for positron emission tomography of neoplasias. Journal of Fluorine Chemistry, 2016, 192, 58-67.	0.9	4

#	Article	IF	Citations
253	Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening. Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, 48-56.	1.4	4
254	Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain. Nuclear Medicine and Biology, 2018, 66, 1-9.	0.3	4
255	Evaluating [68Ga]Ga-p14-032 as a Novel PET Tracer for Diagnosis Cerebral Amyloid Angiopathy. Frontiers in Neurology, 2021, 12, 702185.	1.1	4
256	68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases. Frontiers in Oncology, 2021, 11, 766851.	1.3	4
257	Kit-based preparation of [68Ga]Ga-P16-093 (PSMA-093) using different commercial 68Ge/68Ga generators. Nuclear Medicine and Biology, 2022, 106-107, 1-9.	0.3	4
258	1-123 HIPDM Planar Brain Images Demonstrating Crossed Cerebellar Diaschisis. Clinical Nuclear Medicine, 1990, 15, 34-37.	0.7	3
259	Copper and rhenium complexes of abis (aminoethanethiol) ligand. Polyhedron, 1998, 18, 7-17.	1.0	3
260	A simplified method to determine [99mTc]TRODAT-1 in human plasma. Nuclear Medicine and Biology, 1999, 26, 821-825.	0.3	3
261	Syntheses of Two Potential Ligands for Tcâ€99m Labeling as Diagnosis Agents of Alzheimer's Disease. Chinese Journal of Chemistry, 2003, 21, 824-832.	2.6	3
262	A new single-photon emission computed tomography (SPECT) imaging agent for serotonin transporters: [1251]Flip-IDAM, (2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 869-872.	1.0	3
263	Optimization of solid-phase extraction (SPE) in the preparation of [18F]D3FSP: A new PET imaging agent for mapping $\hat{A}^2$ plaques. Nuclear Medicine and Biology, 2019, 71, 54-64.	0.3	3
264	Synthesis of novel technetium-99m tricarbonyl-HBED-CC complexes and structural prediction in solution by density functional theory calculation. Royal Society Open Science, 2019, 6, 191247.	1.1	3
265	Design, synthesis and evaluation of a novel glutamine derivative (2S,4R)-2-amino-4-cyano-4-[18F]fluorobutanoic acid. New Journal of Chemistry, 2020, 44, 9109-9117.	1.4	3
266	Novel TcvO(III) N2S2 complexes: Interconversion by redox reaction. Nuclear Medicine and Biology, 1996, 23, 589-593.	0.3	2
267	Initial experience in synthesis of ( <scp>)â€4â€[<sup>18</sup>F]fluoroglutamine for clinical application. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 209-214.</scp>	0.5	2
268	Antibodies with high affinity for spiroperidolâ€"ll. cross reactivity with iodobenzamide and domperidone. Molecular Immunology, 1990, 27, 667-677.	1.0	1
269	Rapid screening of nine unradiolabeled candidate compounds as PET brain imaging agents using cassette-wave microdosing and LC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1121, 28-38.	1.2	1
270	Radiation dose to humans from 75Se MOSE ph shift brain imaging agent. International Journal of Nuclear Medicine and Biology, 1983, 10, 55-56.	0.7	0

## HANK F KUNG

#	Article	IF	CITATIONS
271	Synthesis and applications of an aldehyde-containing analog of SCH-23390. Bioconjugate Chemistry, 1990, 1, 394-399.	1.8	O
272	Imaging Monoamine Transporters in the Brain. , 0, , 239-257.		O
273	Characterization of FlipIDAM as a SERT-selective SPECT imaging agent. Nuclear Medicine and Biology, 2013, 40, 879-886.	0.3	O
274	PET Imaging Agents for Alzheimer's Disease. Topics in Medicinal Chemistry, 2017, , 181-197.	0.4	0
275	Single-Molecule Fluorescence Resonance Energy Transfer Studies of β-Amyloid Clusters in Physiological Solutions. World Scientific Lecture and Course Notes in Chemistry, 2017, , 297-311.	0.2	0